PAVMNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

PAVmed Inc.

PAVmed Inc. is a U.S.-based life sciences company organized around a portfolio of medical technologies developed through separate operating subsidiaries. Its business includes diagnostic and cancer-care products, with a focus on devices, tests, and related platforms for unmet clinical needs.

Kysy yhtiöstä
Liikevaihto0,1milj. USD
−97,6 %v/v
Liikevoitto (EBIT)−21,8milj. USD
+51,0 %v/v
EBIT-marginaali−30 712,7%
−29 227,3 %-yks.v/v
Nettotulos0,4milj. USD
−99,0 %v/v
Vapaa kassavirta−5,2milj. USD
+84,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100−80−60−40−20020milj. USD2020: EBIT −23 milj. USD20202021: 0,50 milj. USD2021: EBIT −54 milj. USD20212022: 0,38 milj. USD2022: EBIT −91 milj. USD20222023: 2,5 milj. USD2023: EBIT −69 milj. USD20232024: 3,0 milj. USD2024: EBIT −44 milj. USD20242025: 0,07 milj. USD2025: EBIT −22 milj. USD20250,07−22
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: PAVmed Inc.

Liiketoiminta

Osuus liikevaihdosta
Esophageal cancer screening diagnostics55 %

Non-endoscopic screening and diagnostic tools for Barrett's esophagus and esophageal cancer risk.

Cancer care software/platform services25 %

Subscription-based cancer care platform services tied to Veris Health.

Medical device commercialization10 %

Development and commercialization of proprietary medical devices and related consumables.

Incubator and pipeline development10 %

Early-stage product development and incubation of new healthcare technologies.

Asiakkaat

PAVmed sells into the healthcare ecosystem rather than directly to consumers, with demand driven by physicians, hospitals, clinical researchers, and healthcare systems. Its diagnostic products are aimed at patients who meet screening-risk criteria, while its platform offerings are used by providers and care organizations that manage cancer-related workflows.

Physicians and gastroenterology practices

They buy or order EsoGuard and use EsoCheck-based workflows to screen at-risk patients for Barrett's esophagus.

Hospitals and health systems

They support clinical deployment, patient collection, and research programs around esophageal screening and cancer care.

Clinical research institutions

They participate in validation studies and grant-funded trials evaluating EsoCheck and EsoGuard.

Cancer care organizations

They use Veris Health platform services for cancer care coordination and related subscription workflows.

Strategia

PAVmed’s strategy is to build and commercialize a portfolio of novel healthcare technologies through a parent-company and subsidiary structure. The company emphasizes product development, clinical validation, and targeted financing at the subsidiary level to support each asset’s path to market.

Commercialize EsoGuard and EsoCheckLyhyt aikaväli

Clinical adoption depends on evidence, physician acceptance, and workflow integration.

Build Veris Health subscription platformKeskipitkä aikaväli

Recurring platform revenue can diversify the business beyond single-product diagnostics.

Use flexible subsidiary financingLyhyt aikaväli

Capital can be matched to each asset’s development stage and funding needs.

Maantiede

PAVmed is headquartered in the United States and its reported operating activity is primarily U.S.-based. The company’s products and clinical studies are centered on U.S. physicians, research centers, and healthcare institutions, so domestic regulatory and reimbursement conditions are central to the business.

Riskit

PAVmed depends on successful commercialization of a small number of healthcare assets, so adoption, reimbursement, and regulatory outcomes can materially affect results. The business also carries financing and dilution risk because development-stage medical technology companies often rely on equity, convertible securities, and external capital to fund operations.

Järjestetty vakavuuden mukaan
FDA and regulatory enforcement riskKorkea

EsoGuard is tied to laboratory-developed test assumptions and regulatory enforcement discretion.

Kohdistuu: EsoGuard and related diagnostics

Commercial adoption riskKorkea

Revenue depends on physicians and healthcare systems adopting new screening and care tools.

KohdistuuEsoGuardEsoCheckVeris Health
Financing and dilution riskKorkea

The company has used ATM equity sales and convertible/preferred structures to fund operations.

KohdistuuCommon stockPreferred stockConvertible notes
Clinical evidence riskKeskitaso

Market acceptance of screening products depends on trial outcomes and published validation.

Kohdistuu: NIH-backed EsoCheck/EsoGuard study

Kysy Clarifolta: PAVmed Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for subscription and diagnostic services

Timing of service delivery and collectability judgments affects when revenue is recorded.

Vaikutus: Can create quarter-to-quarter volatility in reported revenue

Fair value measurement of convertible notes and preferred stock

Changes in valuation assumptions flow through other income and expense.

Vaikutus: Can materially affect net results without corresponding cash flow

Debt extinguishment accounting

Exchanges and repayments of convertible debt can create gains or losses on extinguishment.

Vaikutus: Can distort period-to-period comparability

Equity issuance and dilution

ATM sales and preferred conversions increase share count and affect per-share metrics.

Vaikutus: Important for investors modeling ownership dilution

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Precigen, Inc

PGEN · Pharmaceutical Preparations

RenovoRx, Inc.

RNXT · Surgical & Medical Instruments & Apparatus

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

Veru Inc

VERU · Pharmaceutical Preparations

P3 Health Partners Inc.

PIII · Services-Health Services

Päivitetty: 29.4.2026

PAVmed Inc. (Nasdaq) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo